ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Joint Venture
Announcement, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 09 April 2009. International Brachytherapy S.A. (IBt), an
associated company of Eckert & Ziegler AG (ISIN DE0005659700), together
with the Russian state fund Rusnanotech and local partners, will set up a
joint venture to supply Russian prostate cancer patients with therapeutic
implants and other innovative medical devices. A declaration of the
establishment of 'NanoBrachyTech', in which IBt will hold a minority share,
was signed yesterday in Berlin.
The joint venture, which will be based in Moscow, wants to invest up to EUR
23.2 million in the next five years on acquiring manufacturing licenses,
building a production facility and expanding the distribution network. The
special systems for producing the weakly radioactive implants are to be
obtained from Pankow-based Eckert & Ziegler BEBIG GmbH, a world leader in
the field of automation technology for radioactive components.
'The fact that the people in charge in Russia have chosen IBt as their
comprehensive partner and supplier for their modernization work in the
healthcare sector provides proof of the Group's competence and the
international recognition that the treatment of prostate cancer with weakly
radioactive implants has now attained,' said Andreas Eckert, chairman of
the board of Eckert & Ziegler and supervisory board chairman of IBt. 'For
IBT, in addition, the joint venture demonstrates that interesting growth
prospects for innovative radiation technology exist not only within the
European core markets but also in markets which were previously
underdeveloped, such as Russia.'
The Eckert & Ziegler Group, which is predicting turnover of around EUR 100
million for 2009 and has approximately 520 employees, is one of the world's
largest suppliers of isotope technology components for radiation therapy
and nuclear medicine.
Your contact person should you have any queries:
Eckert & Ziegler AG, Karolin Riehle, Public Relations
Robert-Rössle-Str. 10, D-13125 Berlin, Tel.: +49 (0) 30 / 941084-138,
Fax-112
E-mail: karolin.riehle@ezag.de, www.ezag.de
09.04.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------
